Agarwal Surabhi, Elliott Jennifer R, Manzi Susan
Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Curr Rheumatol Rep. 2009 Aug;11(4):241-7. doi: 10.1007/s11926-009-0034-0.
Cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Growing evidence suggests that inflammation plays a key role in the pathogenesis of atherosclerosis from initial endothelial dysfunction to rupture of atheromatous plaques. The increased frequency of atherosclerosis in SLE is likely due to a complex interplay among traditional risk factors, disease-related factors such as medications and disease activity, and inflammatory and immunogenic factors. Identification of these novel risk factors will lead to a better understanding of CVD pathogenesis and may also provide targets for potential treatment strategies. When caring for SLE patients, clinicians should be aware of the increased CVD risk and treat the known modifiable risk factors in addition to controlling disease activity and inflammation.
心血管疾病(CVD)已成为系统性红斑狼疮(SLE)患者发病和死亡的主要原因。越来越多的证据表明,炎症在动脉粥样硬化的发病机制中起关键作用,从最初的内皮功能障碍到动脉粥样斑块破裂。SLE患者动脉粥样硬化发生率增加可能是由于传统危险因素、药物和疾病活动等疾病相关因素以及炎症和免疫原性因素之间复杂的相互作用。识别这些新的危险因素将有助于更好地理解CVD的发病机制,也可能为潜在的治疗策略提供靶点。在照顾SLE患者时,临床医生应意识到CVD风险增加,除了控制疾病活动和炎症外,还应治疗已知的可改变危险因素。